|
Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX ) today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.
More... |
| All times are GMT -7. The time now is 10:58 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021